NCT05764954
A Study of Tumor-Treating Fields (TTFields) in People With Lung Adenocarcinoma
Active, Not Recruiting
PHASE1Ages 22+InterventionalTreatmentMemorial Sloan Kettering Cancer CenterInvestigator-initiated
~12 participants
Updated 2026-05-28 on ClinicalTrials.gov
What's tested:NovoTTF-200T System
At a glance
Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Adverse events, severity and frequency
Measured over 1 year
Conditions
Where it's being run
7 sites across 2 statesNew York4
New Jersey3
Study leadership
- Prasad Adusumilli, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
The participant (or legally acceptable representative \[LAR\], if applicable) provides written informed consent for the study.
The participant is ≥22 years of age on the day of signing informed consent.
The participant has clinical stage 1A2, 1A3 or IB biopsy-proven lung ADC and is eligible for anatomical resection.
The participant has a lung nodule \>1 cm and suspected lung ADC with a plan to undergo biopsy.
The participant with multiple nodules has one nodule that meets the criteria.
The participant has no history of prior malignancy in the chest or has undergone potentially curative therapy with no evidence of that disease recurrence for 5 years since initiation of that therapy.
Exclusion
Patients receiving therapy for concurrent active malignancy
Patients with a history of cardiac arrhythmias and/or pacemaker use
Patients with lung nodules \<1cm
Patients with lung nodules that are pure ground glass opacities (GGOs) of any size
Patients with lung nodules that are \<50% solid of any size
What this trial measures
- Adverse events, severity and frequency1 year
based on Common Terminology Criteria for Adverse Events (CTCAE) version 5.0